絞り込み

18451

広告

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

著者 Mitchell TC , Hamid O , Smith DC , Bauer TM , Wasser JS , Olszanski AJ , Luke JJ , Balmanoukian AS , Schmidt EV , Zhao Y , Gong X , Maleski J , Leopold L , Gajewski TF
J Clin Oncol.2018 Sep 28 ; ():JCO2018789602.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (13view , 0users)
Tumors may evade immunosurveillance through upregulation of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly selective IDO1 enzyme inhibitor. The open-label phase I/II ECHO-202/KEYNOTE-037 trial evaluated epacadostat plus pembrolizumab, a programmed death protein 1 inhibitor, in patients with advanced solid tumors. Phase I results on maximum tolerated dose, safety, tolerability, preliminary antitumor activity, and pharmacokinetics are reported.
PMID: 30265610 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード